Study summary

Chemotherapy alone and radiation alone gave similar long-term survival

EORTC 22033 trial, mature results · 477 people, phase 3 · Published July 2026, Journal of Clinical Oncology

14.9 yearsmedian survival for oligodendroglioma with temozolomide

What was tested

Temozolomide chemotherapy against radiotherapy as first treatment for low-grade glioma, with tumors reclassified by today's molecular criteria.

What they found

Progression-free and overall survival did not differ between arms.
Median survival for oligodendroglioma was 12.9 years with radiation and 14.9 years with temozolomide.
Median survival for IDH-mutant astrocytoma was about 6.6 to 6.7 years either way.

What it means

Shows how long many people live with these tumors and why treatment choices now depend on molecular subtype.

J Clin Oncol, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.